Sunny Worldwide LogisticsIt is a logistics company with more than 20 years of transportation experience, focusing on European, American, Canadian, Australian, Southeast Asia and other markets, and is more than the owner of the cargo owner~
Recently, Trump suddenly threatened in an interview: The United States will impose "small tariffs" on imported drugs first, and raise the tax rate to a maximum of 250% in about a year.
On August 5, Eastern Time, US President Trump made a series of trade policy remarks in an interview with the US Consumer News and Business Channel (CNBC), which attracted widespread attention.
In terms of drug trade, Trump said that the United States will first impose "small tariffs" on imported drugs, and within one to one and a half years, the tax rate will gradually increase to 150%, and then it will reach 250%.
"Made in the United States" may not be affordable
Trump says the move can "reduce drug prices and increase U.S. national security". In this regard, some pharmaceutical industry professionals believe that both goals are difficult to achieve in the face of complex supply chains and high production costs in the United States, andTariff policies themselves also put more uncertainties in the U.S. pharmaceutical industry and businesses.
Recently, many American pharmaceutical companies have stated that they will increase investment in the United States to avoid being imposed - Johnson & Johnson will invest billion to strengthen local production and R&D; Eli Lilly said it will spend billion to build four new pharmaceutical factories in the United States; in addition, multinational pharmaceutical company AstraZeneca said it will invest billion to expand drug production. The total planned investment in US pharmaceutical companies may exceed US0 billion.
Stephen Farelli, head of the global health care department of Dutch International Group, pointed out that even though pharmaceutical companies have achieved local construction in the United States, the cost of manpower, electricity, transportation and other production in the United States is much higher than that of other countries."Made in the United States" may not be affordable.
A large part of the US drug market is occupied by generic drugs. These generic drug manufacturers have very little profit margin, and they will not choose to move their factories back to the United States. Faced with high tariffs, they are more likely to choose to withdraw from the US market, thereby aggravating the US drug shortage.Push up drug prices,These costs will eventually It is reflected on the consumer's bill .
In addition, he also revealed that he would announce tariffs on semiconductors and chips "about next week", but did not give detailed instructions.
Will "significantly" increase tariffs on Indian goods exported to the United States
On the 5th local time, Trump also said that in view of India's continued purchase of Russian oil, he will "significantly" increase the tariffs imposed on Indian goods imported to the United States in the next 24 hours, with the current tax rate of 25%.
Trump did not explicitly mention the new tariff rates on India.
The day before, on the 4th, Trump posted a post on his social media "Real Social" that India not only purchased large quantities of Russian oil, but also sold most of it on the open market to make huge profits. Therefore, he will significantly increase the tariffs India pays to the United States.
Although Trump threatened "punishment", multiple media reported on August 2 that India said it would continue to import oil from Russia. Indian government sources also confirmed that refiners are still purchasing Russian crude oil due to economic factors such as prices and transportation.
At the same time, the EU has new developments in trade policy. According to CCTV News on August 5, European Commission spokesman Olov Gill said that the EU decided to suspend the tariff countermeasures against the United States that were originally scheduled to take effect on August 7, but the option to restart countermeasures is still retained. Jill said the EU is in contact with the United States to implement the trade agreement reached by the two sides last month, and passed necessary legal procedures for this purpose.
However, in recent days, many EU member states have expressed dissatisfaction with the recent trade agreement reached by Europe and the United States, believing that the EU is too weak and there are many things that need to be clarified.
At present, the United States and Europe are refining the framework agreement reached. The EU has previously adopted a list of countermeasures against US goods in case of additional tariffs on US goods in the event of a failure of negotiations.
